Advanced RET-fusion thyroid cancer
Drug | Drug Name | Drug Description |
---|---|---|
DB15822 | Pralsetinib | A RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer. |
DB15685 | Selpercatinib | A RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations. |
Drug | Drug Name | Phase | Status | Count |
---|